Health Canada's acceptance of suzetrigine for review strengthens Vertex Pharmaceuticals' diversification efforts beyond cystic fibrosis into pain and kidney disease markets. While this move supports the company's long-term strategy, near-term performance remains heavily reliant on cystic fibrosis execution and the U.S. uptake of JOURNAVX. Investors are advised to consider the high R&D spend and regulatory risks, alongside future revenue and earnings projections that show a significant upside for VRTX stock.

The U.S. Supreme Court has declined to hear genetic testing company CareDx's appeal in a false-advertising dispute against rival Natera. CareDx had sought to overturn a ruling that denied them $45 million in damages, arguing that courts should presume deception when advertisements are deliberately false. Natera, whose Prospera tests were at the center of the dispute, expressed satisfaction with the outcome.

Paul V. Morris, a former private banker who worked with Jeffrey Epstein at JPMorgan Chase & Co. and Deutsche Bank AG, has left his position as a wealth adviser at Bank of America's Merrill Lynch division. Morris reportedly continued communicating with Epstein after joining Merrill Lynch and leveraged Epstein's network for investment ideas. Although Morris was not accused of any crimes and Epstein was never a Merrill Lynch client, Morris's departure follows reports of his ongoing association with the disgraced financier.

Evergy Director Sandra Aj Lawrence sold 761 shares of Evergy (NASDAQ:EVRG) stock on May 28th and an additional 400 shares on May 29th, reducing her stake by 31.18%. This comes after Evergy reported strong Q1 earnings, beating analyst expectations, and announced a quarterly dividend. Analysts currently rate Evergy as a "Moderate Buy" with an average price target of $89.60.

Wolfe Research has initiated coverage on Thermo Fisher Scientific Inc. (NYSE:TMO) with an Outperform rating and a price target of $535.00, suggesting an 8% upside from its current trading price of $494. The valuation is based on a 20 price-to-earnings multiple applied to the firm’s 2027 EPS estimate, which aligns with the current sector multiple. Despite a recent 30% stock decline from its early 2022 highs, other analysts like KeyBanc maintain an Overweight rating, citing AI tailwinds, while RBC Capital initiated with a Sector Perform rating.

Wolfe Research initiated coverage on Waters Corp. (NYSE:WAT) with an Outperform rating and a price target of $425.00, based on 25 times its 2027 EPS estimate. The firm's analysis notes the company's Q1 performance post-acquisition and its alignment with long-run valuation multiples, despite current perceived overvaluation by InvestingPro. Waters recently reported strong Q1 2026 results, surpassing earnings and revenue forecasts, which led BofA Securities to raise its price target to $370 while maintaining a Neutral rating.

Wolfe Research has initiated coverage on Mettler-Toledo International Inc. (NYSE: MTD) with a "Peerperform" rating. The firm set a fair value range of $1,130 to $1,230, implying a 22 to 24 times 2027 earnings per share, which is a premium to the sector average. Despite solid first-quarter earnings, geopolitical concerns like the Iran conflict have impacted market sentiment for the stock.

Wolfe Research initiated coverage on Danaher Corp. (NYSE:DHR) with a Peerperform rating, setting a fair value range of $165 to $185 per share, which is around the current trading price. The valuation is based on an 18 to 20 times 2027 earnings per share estimate, incorporating the upcoming Masimo acquisition. The firm notes that Danaher, a prominent player in the Life Sciences Tools & Services industry, has a "GOOD" financial health score according to InvestingPro metrics.

KeyCorp's shares traded sideways on the NYSE at the beginning of June 2026 as investors evaluated the bank's Q1 2026 earnings and sector-wide interest rate uncertainties. The stock, trading in the mid-teens, reflects a period of consolidation as market participants discuss the implications of KeyCorp's performance and the Federal Reserve's interest rate stance for regional banks. The article emphasizes that KeyCorp's share price is closely linked to expectations for credit quality, deposit dynamics, and funding costs in its core U.S. markets.

Zacks Research has slightly lowered its FY2026 EPS estimate for Ball Corp to $3.96 per share, despite the company beating Q1 2026 earnings expectations with $0.94 EPS against an estimated $0.85. The stock traded modestly lower on 06/01/2026 but remains around the mid-$50s, with a consensus analyst expectation of $3.98 per share for the full fiscal year. Investors are balancing the strong Q1 performance and core business demand against slight adjustments in long-term profit forecasts and institutional investor positioning.